Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Post-liver transplantation (LT) hepatocellular carcinoma (HCC) recurrence still occurs in approximately 20% of patients and drastically affects their survival. This study aimed to evaluate the efficacy of various treatments for recurrent HCC after LT in a Chinese population.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>A total of 64 HCC patients with tumor recurrence after LT were enrolled in this study. Univariate and multivariate analyses were performed to identify factors affecting post-recurrence survival.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Of the 64 patients with recurrent HCC after LT, those who received radical resection followed by nonsurgical therapy had a median overall survival (OS) of 20.9 months after HCC recurrence, significantly superior to patients who received only nonsurgical therapy (9.4 months) or best supportive care (2.4 months). The one- and two-year OS following recurrence was favorable for patients receiving radical resection followed by nonsurgical therapy (93.8%, 52.6%), poor for patients receiving only nonsurgical therapy (30.8%, 10.8%), and dismal for patients receiving best supportive care (0%, 0%; overall <em>P</em> < 0.001). Median OS in sorafenib-tolerant patients treated with lenvatinib was 19.5 months, far surpassing the patients that discontinued sorafenib or were treated with regorafenib after sorafenib failure (12 months, <em>P</em> < 0.001). Compared with tacrolimus-based immunosuppressive therapy, OS was significantly increased with sirolimus-based therapy at one and two years after HCC recurrence (<em>P</em> = 0.035). Multivariate analysis showed radical resection combined with nonsurgical therapy for recurrent HCC and sorafenib-lenvatinib sequential therapy were independent favorable factors for post-recurrence survival.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Aggressive surgical intervention in well-selected patients significantly improves OS after recurrence. A multidisciplinary treatment approach is required to slow down disease progression for patients with unresectable recurrent HCC.</p>

Combined treatment for the postoperative recurrence of hepatocellular carcinoma

Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience

Metastasis and Recurrence after Surgical Resection of Hepatocellular Carcinoma: Recent Progress in Clinical and Related Basic Aspects

Postoperative therapy options for hepatocellular carcinoma

Option and clinical evaluation of non-surgical therapy of recurrent hepatocellular carcinoma after hepatectomy

Surgical Treatment of Recurrent Hepatocellular Carcinoma.

Prevention and Treatment Strategies of Postoperative Tumor Recurrence after Liver Transplantation for Hepatocellular Carcinoma

[Treatment of Postoperative Recurrence of Hepatocellular Carcinoma with Radiofrequency Ablation Comparing with Repeated Surgical Resection].

Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment.

Current Strategies for Preventing the Recurrence of Hepatocellular Carcinoma after Liver Transplantation

Advancements in the Surgical Treatment of Hepatocellular Carcinoma

Multidisciplinary therapeutic strategies for recurrence and metastasis of liver cancer

Preventive Treatments for Recurrence after Curative Resection of Hepatocellular Carcinoma - A Literature Review of Randomized Control Trials

Progress in Surgical Procedures of Hepatocellular Carcinoma

Reducing liver cancer recurrence rate

Threatment Strategies for Recurrent Hepatocellular Carcinoma Patients: Ablation and its Combination Patterns

The therapy for intrahepatic recurrence after hepatectomy of colorectal liver metastases

Surgical Treatment for Recurrent Hepatocellular Carcinoma: Current Status and Challenges

Treatment of Recurrence Following Surgery for Primary Liver Cancer:A Report of 58 Cases

New Progress of Non-Surgical Treatments for Hepatocellular Carcinoma.

Early Intrahepatic Recurrence of Hepatocellular Carcinoma after Hepatectomy Treated with Re-Hepatectomy, Ablation or Chemoembolization: a Prospective Cohort Study.